目的:监测卵巢癌手术前后血清人附睾分泌蛋白4(human epididymis secretory protein 4,HE4)、CA125(即糖类抗原125)的变化,分析HE4和CA125在卵巢癌诊治中的价值。方法:选取180例卵巢癌患者,根据临床分期分为早期组90例和中晚期组90例,选取90例卵巢良性疾病者作为良性组、90例健康成年女性作为对照组,在手术前后分别监测各组血清HE4和CA125表达水平,统计分析不同检测方法的诊断价值,同时随访卵巢癌患者12个月,对卵巢癌复发患者与未复发患者在手术前后的血清HE4和CA125进行统计分析。结果:血清HE4联合CA125特异度(98.89%)、阳性预测价值(99.27%)显著高于HE4单独检测及CA125单独检测,P<0.05,组间有统计差异;手术后,卵巢癌患者血清HE4、CA125显著下降(P<0.05),但是,在相同监测点,卵巢癌者血清HE4和CA125显著高于对照组和良性组(P<0.05),且中晚期组血清HE4显著高于早期组(P<0.05),良性组血清HE4、CA125略高于对照组,组间无显著差异(P>0.05);卵巢癌复发者血清HE4、CA125显著高于...
【英文摘要】
Objective: To monitor the changes of human epididymis secretory protein 4( HE4),and CA125( carbohydrate antigen 125) of ovarian cancer patients before and after surgery,to analyze the value of HE4 and CA125 in the diagnosis and treatment of ovarian cancer. Methods: The data of 180 patients with ovarian cancer were selected,according to clinical stage,they were divided into early group( 90 cases) and middle-late group( 90 cases),90 cases with benign ovarian disease as benign group and 90 cases of healthy adu...
【更新日期】
2017-10-16
【分类号】
R737.31
【正文快照】
Modern Oncology 2017,25(20):3295-3298【作者单位】中国医科大学附属第一医院肿瘤研究所二室,辽宁沈阳110001卵巢癌作为女性特发性恶性肿瘤之一,是女性高发脏器肿瘤,早期卵巢癌缺乏特异性表现,难以及时发现确诊,而中晚期卵巢癌多预后差、生存质量低,因此积极进行卵巢癌早期诊